cromakalim has been researched along with Vascular Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balus, SF; Buelow, MW; Delaney, M; Dondlinger, L; Hoeppner, C; Lombard, JH; McEwen, ST; Priestley, JR; Weinberg, BD | 1 |
| Azma, T; Dojo, M; Hatano, Y; Iranami, H; Kimoto, Y; Kinoshita, H; Nakahata, K; Yuge, O | 1 |
2 other study(ies) available for cromakalim and Vascular Diseases
| Article | Year |
|---|---|
Reduced angiotensin II levels cause generalized vascular dysfunction via oxidant stress in hamster cheek pouch arterioles.
Topics: Acetylcholine; Angiotensin II; Animals; Arterioles; Blood Pressure; Captopril; Cheek; Cricetinae; Cromakalim; Endothelium, Vascular; Epoprostenol; Glyburide; Iloprost; Male; Mesocricetus; Microscopy; Microscopy, Video; Nitroprusside; Oxidants; Oxygen; Peptidyl-Dipeptidase A; Superoxides; Vascular Diseases | 2013 |
Synthetic peroxisome proliferator-activated receptor-gamma agonists restore impaired vasorelaxation via ATP-sensitive K+ channels by high glucose.
Topics: Adenosine Triphosphate; Aged; Cromakalim; Dose-Response Relationship, Drug; Female; Glucose; Humans; Male; Middle Aged; Potassium Channels; PPAR gamma; Vascular Diseases; Vasodilation | 2006 |